BiomX Inc. (PHGE)
NYSEAMERICAN: PHGE · Real-Time Price · USD
0.5459
+0.0062 (1.15%)
Apr 21, 2025, 4:00 PM EDT - Market closed
Company Description
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials.
The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
BiomX Inc.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Jonathan Solomon |
Contact Details
Address: 22 Einstein Street, Floor 4 Ness Ziona, 7414003 Israel | |
| Phone | 972 7 2394 2377 |
| Website | biomx.com |
Stock Details
| Ticker Symbol | PHGE |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739174 |
| CUSIP Number | 09090D103 |
| ISIN Number | US09090D1037 |
| Employer ID | 82-3364020 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jonathan Eitan Solomon MBA | Chief Executive Officer and Director |
| Marina Wolfson CPA | Chief Financial Officer and Secretary |
| Dr. Merav Bassan Ph.D. | Chief Development Officer |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Inbal Benjamini-Elran | C.H.R.O |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 10-K | Annual Report |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 17, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 4, 2025 | SCHEDULE 13G/A | Filing |